Glucocorticoid receptor point mutation V571M facilitates coactivator and ligand binding by structural rearrangement and stabilization

Molecular Endocrinology

Volumn 19, Issue 8, 2005, Pages 1960-1977

  Carlsson, Peter ^a,b,c   Koehler, Konrad F ^a   Nilsson, Lennart ^b  

^a Novum ^*  (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Karo Bio   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; ESTROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; GLUTAMINE; HISTONE H1; HISTONE H3; LIGAND; METHIONINE; PEPTIDE;

ARTICLE; BINDING AFFINITY; BINDING SITE; COMPUTER SIMULATION; CORRELATION ANALYSIS; CRYSTAL STRUCTURE; ENTROPY; GENE REARRANGEMENT; INTERMETHOD COMPARISON; LIGAND BINDING; MOLECULAR DYNAMICS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN CONFORMATION;

ALLOSTERIC SITE; BINDING SITES; CELL NUCLEUS; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DIMERIZATION; DRUG DESIGN; HUMANS; HYDROGEN BONDING; LIGANDS; MODELS, MOLECULAR; MUTATION; PEPTIDES; POINT MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, GLUCOCORTICOID; TIME FACTORS; TRANS-ACTIVATION (GENETICS);

EID: 23744511541     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2004-0203     Document Type: Article

References (41)

1. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758
2. Lind U, Greenidge P, Gustafsson JA, Wright APH, Carlstedt-Duke J 1999 Valine 571 functions as a regional organizer in programming the glucocorticoid receptor for differential binding of glucocorticoids and mineralocorticoids. J Biol Chem 274:18515-18523
3. Kunz S, Sandoval R, Carlsson P, Carlstedt-Duke J, Bloom JW, Miesfeld RL 2003 Identification of a novel glucocorticoid receptor mutation in budesonide-resistant human bronchial epithelial cells. Mol Endocrinol 17:2566-2582
4. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler TG, Parks DJ, Stewart EL, Willson TM, Lambert MH, Moore JT, Pearce KH, Xu HE 2002 Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110:93-105
5. Kauppi B, Jakob C, Farnegardh M, Yang J, Ahola H, Alarcon M, Calles K, Engstrom O, Harlan J, Muchmore S, Ramqvist AK, Thorell S, Ohman L, Greer J, Gustafsson JA, Carlstedt-Duke J, Carlquist M 2003 The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain-RU-486 induces a transconformation that leads to active antagonism. J Biol Chem 278:22748-22754
6. Warnmark A, Treuter E, Wright APH, Gustafsson JA 2003 Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation. Mol Endocrinol 17:1901-1909
7. Freire E 1998 Statistical thermodynamic linkage between conformational and binding equilibria. Adv Protein Chem 51:255-279
8. Teague SJ 2003 Implications of protein flexibility for drug discovery. Nat Rev Drug Discov 2:527-541
9. Kumar S, Ma BY, Tsai CJ, Sinha N, Nussinov R 2000 Folding and binding cascades: dynamic landscapes and population shifts. Protein Sci 9:10-19
10. Pissios P, Tzameli I, Moore DD 2001 New insights into receptor ligand binding domains from a novel assembly assay. J Steroid Biochem Mol Biol 76:3-7
11. Holt JA, Consiler TG, Williams SP, Ayscue AH, Leesnitzer LM, Wisely GB, Billin AN 2003 Helix 1/8 interactions influence the activity of nuclear receptor ligand-binding domains. Mol Endocrinol 17:1704-1714
12. Roux S, Terouanne B, Balaguer P, JausonsLoffreda N, Pons M, Chambon P, Gronemeyer H, Nicolas JC 1996 Mutation of isoleucine 747 by a threonine alters the ligand responsiveness of the human glucocorticoid receptor. Mol Endocrinol 10:1214-1226
13. Roux S, Terouanne B, Couette B, Rafestin-Oblin ME, Nicolas JC 1999 Conformational change in the human glucocorticoid receptor induced by ligand binding is altered by mutation of isoleucine 747 by a threonine. J Biol Chem 274:10059-10065
14. Vottero A, Kino T, Combe H, Lecomte P, Chrousos GP 2002 A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators. J Clin Endocrinol Metab 87:2658-2667
15. Dunbrack RL, Cohen FE 1997 Bayesian statistical analysis of protein side-chain rotamer preferences. Protein Sci 6:1661-1681
16. Nettles KW, Sun J, Radek JT, Sheng S, Rodriguez AL, Katzenellenbogen JA, Katzenellenbogen BS, Greene GL 2004 Allosteric control of ligand selectivity between estrogen receptors a and β: implications for other nuclear receptors. Mol Cell 13:317-327
17. Zhang S, Liang X, Danielsen M 1996 Role of the C terminus of the glucocorticoid receptor in hormone binding and agonist/antagonist discrimination. Mol Endocrinol 10:24-34
18. Langley E, Kemppainen JA, Wilson EM 1998 Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J Biol Chem 273:92-101
19. Shulman AI, Larson C, Mangelsdorf DJ, Ranganathan R 2004 Structural determinants of allosteric ligand activation in RXR heterodimers. Cell 116:417-429
20. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937
21. Shiau AK, Barstad D, Radek JT, Meyers MJ, Nettles KW, Katzenellenbogen BS, Katzenellenbogen JA, Agard DA, Greene GL 2002 Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol 9:359-364
22. Warnmark A, Treuter E, Gustafsson JA, Hubbard RE, Brzozowski AM, Pike ACW 2002 Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor α. J Biol Chem 277:21862-21868
23. Leduc AM, Trent JO, Wittliff JL, Bramlett KS, Briggs SL, Chirgadze NY, Wang Y, Burris TP, Spatola AF 2003 Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proc Natl Acad Sci USA 100:11273-11278
24. Gangloff M, Ruff M, Eiler S, Duclaud S, Wurtz JM, Moras D 2001 Crystal structure of a mutant hER α ligand-binding domain reveals key structural features for the mechanism of partial agonism. J Biol Chem 276:15059-15065
25. Eiler S, Gangloff M, Duclaud S, Moras D, Ruff M 2001 Overexpression, purification, and crystal structure of native ER[alpha] LBD. Protein Expr Purif 22:165-173
26. Carlson KE, Choi I, Gee A, Katzenellenbogen BS, Katzenellenbogen JA 1997 Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry 36:14897-14905
27. Bourguet W, Germain P, Gronemeyer H 2000 Nuclear receptor ligand-binding domains three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci 21:381-388
28. Draper MW 2003 The role of selective estrogen receptor modulators (SERMs) in postmenopausal health. Ann NY Acad Sci 997:373-377
29. Shang YF, Brown M 2002 Molecular determinants for the tissue specificity of SERMs. Science 295:2465-2468
30. Brunger AT, Karplus M 1988 Polar hydrogen positions in proteins: empirical energy placement and neutron-diffraction comparison. Proteins 4:148-156
31. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M 1983 CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 4:187-217
32. Jorgensen WL, Chandrasekhar J, Madura J, Impey RW, Klein ML 1983 Comparison of simple potential functions for simulating liquid water. J Chem Phys 79:926-935
33. Sen S, Nilsson L 1999 Structure, interaction, dynamics and solvent effects on the DNA-EcoRI complex in aqueous solution from molecular dynamics simulation. Biophys J 77:1782-1800
34. Steinbach PJ, Brooks BR 1993 Protein hydration elucidated by molecular-dynamics simulation. Proc Natl Acad Sci USA 90:9135-9139
35. MacKerell Jr AD, Bashford D, Bellott M, Dunbrack Jr RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczera K, Lau FTK, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher III WE, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiorkiewicz-Kuczera J, Yin D, Karplus M 1998 All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102:3586-3616
36. Brooks III C, Karplus M 1983 Deformable stochastic boundaries in molecular dynamics. J Chem Phys 79:6312-6325
37. Ryckaert J-P, Ciccotti G, Berendsen HJC 1977 Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comp Physiol 23:327-341
38. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D 1995 Crystal-structure of the RAR-γ ligand-binding domain bound to all-trans-retinoic acid. Nature 378:681-689
39. Kraulis PJ 1991 Molscript - a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 24:946-950
40. Williams SP, Sigler PB 1998 Atomic structure of progesterone complexed with its receptor. Nature 393:392-396
41. DeLano WL The PyMOL molecular graphics system. San Carlos, CA: DeLano Scientific LLC